|Bid||121.26 x 200|
|Ask||121.38 x 200|
|Day's Range||109.46 - 123.26|
|52 Week Range||96.18 - 149.34|
|PE Ratio (TTM)||62.13|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alexion Pharmaceuticals reported adjusted profit of $1.68 per share and $930.9 million in sales for its first quarter.
When the company moves into its new headquarters in the Seaport District this summer, it will become the state’s third most valuable drugmaker.
Alexion exceeds both earnings and sales expectations in the first quarter of 2018.The company also raised revenue and earnings guidance for 2018.
With earnings season in full swing, pharma stocks got a boost today from AbbVie (ABBV), and Alexion Pharmaceuticals (ALXN), although Bristol-Myers Squibb (BMY) has given up its early gains. AbbVie said ...
On a per-share basis, the New Haven, Connecticut-based company said it had net income of $1.11. Earnings, adjusted for one-time gains and costs, came to $1.68 per share. The results exceeded Wall Street ...
Rising levels of market volatility and subsequent selling pressure have started to take hold of the strongest performing market segments such as biotechnology. The sudden shift in sentiment now has some active traders talking about a long-term shift in trend. Traders who want to gain exposure to a broad range of biotechnology companies often look to exchange-traded products such as the iShares Nasdaq Biotechnology ETF.
Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.
Venture capitalists are betting $37 million that a trio of former Alexion Pharmaceuticals Inc. executives will lead startup Rallybio LLC to success in the rare-disease market.
Alexion Pharmaceuticals (ALXN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Alexion slid to a 10-month low Friday after reports emerged that Brazil's government will allow drugmakers to produce biologic copies of Alexion's blockbuster drug Soliris.
The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) is almost flat for the week after adding about 5 percent in the week ended April 13. Will the following catalytic events lead to a resumption ...
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Alexion Pharmaceuticals (ALXN) is one of the leading biotechnology firms. Soliris is approved to treat aHUS (atypical hemolytic uremic syndrome) and PHN (paroxysmal nocturnal hemoglobinuria). Alexion’s latest acquisition of Wilson Therapeutics is a turnaround strategy that’s being implemented to restructure Alexion’s performance and investors’ sentiments in the market.
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced the acquisition of Wilson Therapeutics, which is developing a “first-of-its-kind” treatment for Wilson disease. Currently, Wilson disease is treated with copper chelators, Penicillamine or Trientine, to remove copper from serum. The drug has the potential to become the standard of care for Wilson disease patients.
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced the acquisition of Wilson Therapeutics. Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.
Wilson Therapeutics is a biopharmaceutical company focused on developing rare disease therapies. The company is listed on the Nasdaq Stockholm Exchange and has a market capitalization of 6.5 billion Swedish kronor. Wilson Therapeutics is developing a novel therapy to treat Wilson disease, which is a rare genetic and chronic disorder characterized by an accumulation of copper in the brain, liver, and other vital organs.
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.
Alexion (ALXN) announces that the company will acquire Sweden-based Wilson Therapeutics for $855 million, the latest company to join the ongoing acquisitions spree in the biotech sector.
Alexion Pharmaceuticals will snap up Wilson Therapeutics in a move that helps it diversify from its blockbuster franchise and compete with Valeant and Teva.
Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.
Keith Bliss of Cuttone and Company joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.